| |
| |
|
| Insider
Information: |
Li Dean Y |
| Relationship: |
Director |
| City: |
Kenilworth |
| State: |
NJ |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
105,331 |
|
|
Indirect Shares
|
3,112,844 |
|
|
| Direct
Value |
$6,623,569 |
|
|
|
Indirect Value
|
$29,322,990 |
|
|
| Total
Shares |
3,218,175 |
|
|
| Total
Value |
$35,946,559 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
|
|
| Stock
price went down : |
|
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Merck & Co Inc |
MRK |
Executive VP & Preside... |
2024-02-09 |
46,242 |
|
0 |
Premium* |
|
|
Recursion Pharmaceuticals, Inc. |
RXRX |
Director |
2024-04-01 |
59,089 |
2024-04-01 |
3,112,844 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
48 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 2
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| MRK |
Merck & Co Inc |
Executive VP & President, MRLO |
• – – |
2021-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
7,170 |
|
- |
|
| RXRX |
Recursion Pharmaceuticals... |
Director |
– • – |
2021-04-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
582,501 |
|
- |
|
| RXRX |
Recursion Pharmaceuticals... |
Director |
– • – |
2021-04-15 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
3,166,665 |
|
- |
|
| MRK |
Merck & Co Inc |
Executive VP & President, MRL |
• • – |
2021-02-26 |
4 |
A |
$72.62 |
$253,081 |
D/D |
3,485 |
10,655 |
0 |
- |
|
| RXRX |
Recursion Pharmaceuticals... |
Director |
– • – |
2021-04-16 |
4 |
A |
$0.00 |
$0 |
D/D |
13,889 |
596,390 |
0 |
- |
|
| RXRX |
Recursion Pharmaceuticals... |
Director |
– • – |
2021-04-20 |
4 |
A |
$0.00 |
$0 |
D/D |
596,390 |
596,390 |
0 |
- |
|
| RXRX |
Recursion Pharmaceuticals... |
Director |
– • – |
2021-04-20 |
4 |
D |
$0.00 |
$0 |
D/D |
(596,390) |
0 |
0 |
- |
|
| RXRX |
Recursion Pharmaceuticals... |
Director |
– • – |
2021-04-20 |
4 |
A |
$0.00 |
$0 |
I/I |
3,222,048 |
1,350,000 |
0 |
- |
|
| RXRX |
Recursion Pharmaceuticals... |
Director |
– • – |
2021-04-20 |
4 |
D |
$0.00 |
$0 |
I/I |
(3,222,048) |
0 |
0 |
- |
|
| RXRX |
Recursion Pharmaceuticals... |
Director |
– • – |
2021-04-20 |
4 |
A |
$0.00 |
$0 |
I/I |
55,383 |
1,422,048 |
0 |
- |
|
| MRK |
Merck & Co Inc |
Executive VP & President, MRL |
• • – |
2021-05-01 |
4 |
D |
$74.50 |
$26,373 |
D/D |
(354) |
11,361 |
0 |
- |
|
| MRK |
Merck & Co Inc |
Executive VP & President, MRL |
• • – |
2021-05-01 |
4 |
OE |
$74.50 |
$76,735 |
D/D |
1,030 |
11,715 |
0 |
- |
|
| MRK |
Merck & Co Inc |
Executive VP & President, MRL |
• • – |
2021-05-03 |
4 |
OE |
$74.50 |
$55,875 |
D/D |
750 |
12,111 |
0 |
- |
|
| MRK |
Merck & Co Inc |
Executive VP & President, MRL |
• • – |
2021-05-03 |
4 |
D |
$74.50 |
$19,147 |
D/D |
(257) |
11,854 |
0 |
- |
|
| MRK |
Merck & Co Inc |
Executive VP & President, MRL |
• • – |
2021-05-04 |
4 |
OE |
$75.98 |
$52,730 |
D/D |
694 |
12,548 |
0 |
- |
|
| MRK |
Merck & Co Inc |
Executive VP & President, MRL |
• • – |
2021-05-04 |
4 |
D |
$75.98 |
$18,083 |
D/D |
(238) |
12,310 |
0 |
- |
|
| RXRX |
Recursion Pharmaceuticals... |
Director |
– • – |
2021-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
330 |
596,720 |
0 |
- |
|
| RXRX |
Recursion Pharmaceuticals... |
Director |
– • – |
2021-10-01 |
4 |
A |
$0.00 |
$0 |
D/D |
543 |
597,263 |
0 |
- |
|
| RXRX |
Recursion Pharmaceuticals... |
Director |
– • – |
2021-11-17 |
4 |
AS |
$20.04 |
$112,736 |
D/D |
(5,626) |
591,637 |
0 |
% |
|
| RXRX |
Recursion Pharmaceuticals... |
Director |
– • – |
2021-11-19 |
4 |
AS |
$20.20 |
$272,226 |
D/D |
(13,474) |
578,163 |
0 |
% |
|
| RXRX |
Recursion Pharmaceuticals... |
Director |
– • – |
2021-12-07 |
4 |
AS |
$20.44 |
$325,630 |
I/I |
(15,900) |
1,315,000 |
0 |
% |
|
| RXRX |
Recursion Pharmaceuticals... |
Director |
– • – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
659 |
597,922 |
0 |
- |
|
| MRK |
Merck & Co Inc |
Executive VP & President, MRL |
• • – |
2022-02-24 |
4 |
A |
$73.51 |
$222,221 |
D/D |
3,023 |
15,462 |
0 |
- |
|
| RXRX |
Recursion Pharmaceuticals... |
Director |
– • – |
2022-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,544 |
599,466 |
0 |
- |
|
| MRK |
Merck & Co Inc |
Executive VP & President, MRL |
• • – |
2022-05-01 |
4 |
OE |
$88.69 |
$94,100 |
D/D |
1,061 |
16,589 |
0 |
- |
|
48 Records found
|
|
Page 1 of 2 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
